NOAC in patients with VTE and polycythemia vera or essential thrombocythemia
Last Updated: Friday, September 3, 2021
Among patients with essential thrombocythemia and polycythemia vera who have experienced venous thromboembolism (VTE), non-vitamin K antagonist oral anticoagulants may be efficacious in preventing VTE. During a median follow-up of 30 months, low numbers of thrombotic events—including deep vein thrombosis episodes, ischemic stroke, and major bleeding—were reported among patients receiving apixaban, rivaroxaban, or dabigatran.
Advertisement
News & Literature Highlights
